-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Merck (Merck is the company name of Merck Corporation in Rowe, New Jersey, USA) announced that its new indications for the nine-valent human papillomavirus vaccine (Saccharomyces cerevisiae) (hereinafter referred to as "nine-valent HPV vaccine") have been approved by the State Drug Administration of China, marking that the applicable population of Merck nine-valent HPV vaccine has also been expanded to women
Nine-valent HPV vaccines use a three-dose immunization program for the prevention of cervical cancer caused by HPV 16, 18, 31, 33, 45, 52 and 58; Cervical intraepithelial neoplasia (grade CIN1/2/3) and cervical adenocarcinoma in situ (AIS) caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and persistent infections
Cervical cancer is one
Professor Qiao Youlin of the School of Group Medicine and Public Health of the Chinese Academy of Medical Sciences and Peking Union Medical College pointed out that adolescent girls vaccinated with HPV vaccines are easy to stimulate a better immune response [3]-,[4],[5],[7],[8], and women who have not had sex will get the best preventive effect [9].
"In order to reduce the threat of cervical cancer to women's health, in recent years, China attaches great importance to the comprehensive
Dr.
Anna Van Acker, Senior Vice President of Merck Worldwide and President of Merck China, said: "Eliminating cervical cancer is a vision shared by all of humanity, and Merck is committed to protecting the health
Merck (Merck is the company name of Merck Corporation in Rowe, New Jersey, USA) announced that its new indications for the nine-valent human papillomavirus vaccine (Saccharomyces cerevisiae) (hereinafter referred to as "nine-valent HPV vaccine") have been approved by the State Drug Administration of China, marking that the applicable population of Merck nine-valent HPV vaccine has also been expanded to women
Nine-valent HPV vaccines use a three-dose immunization program for the prevention of cervical cancer caused by HPV 16, 18, 31, 33, 45, 52 and 58; Cervical intraepithelial neoplasia (grade CIN1/2/3) and cervical adenocarcinoma in situ (AIS) caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and persistent infections
Cervical cancer is one
Professor Qiao Youlin of the School of Group Medicine and Public Health of the Chinese Academy of Medical Sciences and Peking Union Medical College pointed out that adolescent girls vaccinated with HPV vaccines are easy to stimulate a better immune response [3]-,[4],[5],[7],[8], and women who have not had sex will get the best preventive effect [9].
"In order to reduce the threat of cervical cancer to women's health, in recent years, China attaches great importance to the comprehensive
Dr.
Anna Van Acker, Senior Vice President of Merck Worldwide and President of Merck China, said: "Eliminating cervical cancer is a vision shared by all of humanity, and Merck is committed to protecting the health
If this article violates your rights, please contact us
